Clinical trial
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
NCT01096342 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- December 31, 2012
- Enrollment
- 16 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
refractory multiple myeloma